119 related articles for article (PubMed ID: 23993328)
21. Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.
Zhou S; Liao H; Liu M; Feng G; Fu B; Li R; Cheng M; Zhao Y; Gong P
Bioorg Med Chem; 2014 Nov; 22(22):6438-52. PubMed ID: 25438768
[TBL] [Abstract][Full Text] [Related]
22. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
[TBL] [Abstract][Full Text] [Related]
23. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
24. Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities.
Wang Y; Zhan Z; Jiang X; Peng X; Shen Y; Chen F; Ji Y; Liu W; Shi Y; Duan W; Ding J; Ai J; Geng M
Oncotarget; 2016 Jun; 7(25):38091-38104. PubMed ID: 27191264
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y
Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123
[TBL] [Abstract][Full Text] [Related]
26. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
Liu Y; Jin S; Peng X; Lu D; Zeng L; Sun Y; Ai J; Geng M; Hu Y
Eur J Med Chem; 2016 Jan; 108():322-333. PubMed ID: 26698536
[TBL] [Abstract][Full Text] [Related]
27. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.
Mohyeldin MM; Akl MR; Ebrahim HY; Dragoi AM; Dykes S; Cardelli JA; El Sayed KA
Oncotarget; 2016 May; 7(22):32247-73. PubMed ID: 27086914
[TBL] [Abstract][Full Text] [Related]
28. Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.
Peterson EA; Teffera Y; Albrecht BK; Bauer D; Bellon SF; Boezio A; Boezio C; Broome MA; Choquette D; Copeland KW; Dussault I; Lewis R; Lin MH; Lohman J; Liu J; Potashman M; Rex K; Shimanovich R; Whittington DA; Vaida KR; Harmange JC
J Med Chem; 2015 Mar; 58(5):2417-30. PubMed ID: 25699405
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461.
Wu JF; Liu MM; Huang SX; Wang Y
Bioorg Med Chem Lett; 2015 Aug; 25(16):3251-5. PubMed ID: 26077488
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of millepachine derivatives as a new class of tubulin polymerization inhibitors.
Wang G; Peng F; Cao D; Yang Z; Han X; Liu J; Wu W; He L; Ma L; Chen J; Sang Y; Xiang M; Peng A; Wei Y; Chen L
Bioorg Med Chem; 2013 Nov; 21(21):6844-54. PubMed ID: 23993668
[TBL] [Abstract][Full Text] [Related]
33. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
34. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors.
Qi B; Tao H; Wu D; Bai J; Shi Y; Gong P
Arch Pharm (Weinheim); 2013 Aug; 346(8):596-609. PubMed ID: 23843304
[TBL] [Abstract][Full Text] [Related]
36. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
37. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.
Boezio AA; Berry L; Albrecht BK; Bauer D; Bellon SF; Bode C; Chen A; Choquette D; Dussault I; Fang M; Hirai S; Kaplan-Lefko P; Larrow JF; Lin MH; Lohman J; Potashman MH; Qu Y; Rex K; Santostefano M; Shah K; Shimanovich R; Springer SK; Teffera Y; Yang Y; Zhang Y; Harmange JC
Bioorg Med Chem Lett; 2009 Nov; 19(22):6307-12. PubMed ID: 19819693
[TBL] [Abstract][Full Text] [Related]
38. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
Liu Z; Wang R; Guo R; Hu J; Li R; Zhao Y; Gong P
Bioorg Med Chem; 2014 Jul; 22(14):3642-53. PubMed ID: 24882675
[TBL] [Abstract][Full Text] [Related]
40. Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.
Zhang D; Ai J; Liang Z; Zhu W; Peng X; Chen X; Ji Y; Jiang H; Luo C; Geng M; Liu H
Bioorg Med Chem Lett; 2013 Apr; 23(8):2408-13. PubMed ID: 23474386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
